Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta‐blockers
Open Access
- 24 March 2010
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 12 (4), 404-410
- https://doi.org/10.1093/eurjhf/hfq032
Abstract
Aims The aim of this study is to compare the effects of a 24 h intravenous infusion of levosimendan and a 48 h infusion of dobutamine on invasive haemodynamics in patients with acutely decompensated chronic NYHA class III–IV heart failure. All patients were receiving optimal oral therapy including a β‐blocker. Methods and results This was a multinational, randomized, double‐blind, phase IV study in 60 patients; follow‐up was 1 month. There was a significant increase in cardiac index and a significant decrease in pulmonary capillary wedge pressure (PCWP) at 24 and 48 h for both dobutamine and levosimendan. The improvement in cardiac index with levosimendan was not significantly different from dobutamine at 24 h (P = 0.07), but became significant at 48 h (0.44 ± 0.56 vs. 0.66 ± 0.63 L/min/m2; P = 0.04). At 24 h, the reduction in the mean change in PCWP from baseline was similar for levosimendan and dobutamine, however, at 48 h the difference was more marked for levosimendan (−3.6 ± 7.6 vs. −8.3 ± 6.7 mmHg; P = 0.02). No difference was observed between the groups for change in NYHA class, β‐blocker use, hospitalizations, treatment discontinuations or rescue medication use. Reduction in B‐type natriuretic peptide (BNP) was significantly greater with levosimendan at 48 h (P = 0.03). According to physician's assessment, the improvement in fatigue (P = 0.01) and dyspnoea (P = 0.04) was in favour of dobutamine treatment, and hypotension was significantly more frequent with levosimendan (P = 0.007). No increase in atrial fibrillation or ventricular tachycardia was seen in either group. Conclusion A 24 h levosimendan infusion achieved haemodynamic and neurohormonal improvement that was at least comparable at 24 h and superior at 48 h to a 48 h dobutamine infusion.Keywords
This publication has 17 references indexed in Scilit:
- Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β‐blockers in SURVIVE†European Journal of Heart Failure, 2009
- Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart FailureJAMA, 2007
- Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failureHeart, 2003
- Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialThe Lancet, 2002
- Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart FailureCirculation, 2000
- Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendanJournal of Molecular and Cellular Cardiology, 1995
- Down-regulation of -adrenergic receptors on mononuclear leukocytes induced by dobutamine treatment in patients with congestive heart failureEuropean Heart Journal, 1993
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988
- Tolerance to dobutamine after a 72 hour continuous infusionAmerican Journal Of Medicine, 1980
- Human Experimentation: Code of Ethics of W.M.ABMJ, 1964